Home Endotronix Inc.

Endotronix Inc.

Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution

The funds will be used to support the landmark PROACTIVE-HF IDE clinical trial of the Cordella® Pulmonary Artery Sensor System (Cordella Sensor) and commercialization of the Cordella® Heart Failure System (Cordella System).

Endotronix Receives FDA Approval for PROACTIVE-HF Pivotal IDE Trial

The innovative trial is designed to expedite Pre-Market Approval (PMA) of the Cordella Sensor and provide evidence to inform a national coverage decision from the Centers for Medicare & Medicaid Services (CMS). The company plans to begin enrollment in the trial in the third quarter of 2019.

Endotronix Enrolls First Patient in SIRONA II CE Mark Trial

“SIRONA II builds on the success of our First-in-Human trial and expands our experience with the Cordella Sensor as we progress towards receiving our CE Mark,” stated Katrin Leadley, MD, Chief Medical Officer of Endotronix.